What are the key takeaways from GRDN's 2024 earnings reports?

Guardian Pharmacy Services (NYSE: GRDN) faced a challenging year in 2024, with earnings per share (EPS) missing expectations and a significant net loss. However, revenue showed growth, and strategic expansions are supporting the company's market position. 1. **Financial Performance**: - Guardian reported a net loss of $87.3 million for the year, a 465% decrease from the $23.9 million profit in 2023. - EPS missed analyst estimates by 48%, with a loss of $1.41 per share. - Revenue increased by 17% to $1.23 billion compared to the previous year. - The company's largest operating expense was General & Administrative costs, amounting to $302.9 million, which is 91% of total expenses. 2. **Revenue Segmentation**: The only revenue segment for Guardian was Pharmacy Services, contributing $1.23 billion. 3. **Strategic Developments**: - Guardian expanded its footprint with 9 new pharmacy locations and 2 acquisitions. - The company's stock price saw a minor decline of 0.49% in aftermarket trading following the earnings release. 4. **Market Position and Outlook**: - Despite the challenges, Guardian's strategic expansions and innovations underline its strong market position. - The company projects its 2025 revenue to be between $1.33 billion and $1.35 billion. 5. **Industry Comparison**: Guardian's revenue growth of 6.1% per annum over the next three years is slightly higher than the 4.8% growth forecast for the Consumer Retailing industry in the US. In conclusion, Guardian Pharmacy Services faced a tough year with significant losses but showed resilience through strategic expansions. While the EPS miss and net loss are concerning, the company's revenue growth and strategic direction suggest a potential path to recovery.